PDL BioPharma to Present at Upcoming Investor Conferences - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

PDL BioPharma to Present at Upcoming Investor Conferences

  • SPONSORED BY SOUTHEAST HEALTHMore>>

  • Beshear: 413,000 sign up for health care in Ky

    Beshear: 413,000 sign up for health care in Ky

    Tuesday, April 22 2014 3:22 PM EDT2014-04-22 19:22:11 GMT
    Kentucky Gov. Steve Beshear says more than 413,410 people have signed up for health insurance through Kentucky's marketplace in the first enrollment period that ended March 31.
    Kentucky Gov. Steve Beshear says more than 413,410 people have signed up for health insurance through Kentucky's marketplace in the first enrollment period that ended March 31.
  • Too little sleep may add to teen health problems

    Too little sleep may add to teen health problems

    Many teens from lower- and middle-income homes get too little sleep, potentially adding to the problems of kids already at risk for health issues, new research finds.
    Many teens from lower- and middle-income homes get too little sleep, potentially adding to the problems of kids already at risk for health issues, new research finds.
  • BJC changes charity care standards

    BJC changes charity care standards

    Sunday, April 20 2014 1:01 PM EDT2014-04-20 17:01:10 GMT
    Charity care has long been a core mission of BJC HealthCare, but the St. Louis area's largest employer is cutting back amid increasing financial pressures.
    Charity care has long been a core mission of BJC HealthCare, but the St. Louis area's largest employer is cutting back amid increasing financial pressures.

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE PDL BioPharma, Inc.

INCLINE VILLAGE, Nev., Feb. 19, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

2014 RBC Capital Markets' Healthcare Conference
Wednesday, February 26th, 2014
9:30 a.m. EST
New York, NY

Cowen and Company 34th Annual Health Care Conference
Wednesday, March 5th, 2014
10:00 a.m. EST
Boston, MA

To access the live and subsequently archived webcasts of the presentations, go to the Company's website at http://www.pdl.com and go to "Events and Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. The archived webcast will be available for seven days following each presentation.

About PDL BioPharma, Inc.

PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue. PDL is currently focused on intellectual property asset management, acquiring new income generating assets, and maximizing value for its shareholders.

The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada.
In 2011, PDL initiated a strategy to bring in new income generating assets from the healthcare sector. To accomplish this goal, PDL seeks to provide non-dilutive growth capital and financing solutions to late stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL continues to pursue this strategic initiative for which it has already deployed approximately $500 million to date. PDL is focused on the quality of the income generating assets and potential returns on investment.
For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

310 Broadway
Cape Girardeau, MO 63701

FCC Public File
publicfile@kfvs12.com
573-335-1212
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KFVS12. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.